MX2016006551A - Preparacion de anticuerpos de cultivos de celula de ovario de hamster chino para conjugacion. - Google Patents

Preparacion de anticuerpos de cultivos de celula de ovario de hamster chino para conjugacion.

Info

Publication number
MX2016006551A
MX2016006551A MX2016006551A MX2016006551A MX2016006551A MX 2016006551 A MX2016006551 A MX 2016006551A MX 2016006551 A MX2016006551 A MX 2016006551A MX 2016006551 A MX2016006551 A MX 2016006551A MX 2016006551 A MX2016006551 A MX 2016006551A
Authority
MX
Mexico
Prior art keywords
antibody
cho cell
oxidizing enzyme
conjugation
purification
Prior art date
Application number
MX2016006551A
Other languages
English (en)
Inventor
Meyer Damon
Lyon Robert
Beam Kevin
VALLIERE-DOUGLASS John
Hayes Bradley
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2016006551A publication Critical patent/MX2016006551A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/03—Oxidoreductases acting on sulfur groups as donors (1.8) with oxygen as acceptor (1.8.3)
    • C12Y108/03002—Thiol oxidase (1.8.3.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se basa en parte en la observación de que una enzima oxidante de la célula CHO, particularmente QSOX1, puede sobrevivir un proceso de purificación de anticuerpo aparentemente rigurosos para reducir la eficiencia de la posterior conjugación del anticuerpo con un fármaco. Si la enzima oxidante sobrevive el procedimiento de purificación depende de cuáles técnicas de purificación se emplean que puede variar de un anticuerpo a otro. Sabiendo que la contaminación con una enzima oxidante de la célula CHO es un problema potencial para la posterior conjugación, un esquema de purificación adecuado puede visualizarse para cualquier anticuerpo que elimina o al menos reduce la(s) enzima(s) oxidante(s) a un nivel aceptable.
MX2016006551A 2013-11-25 2014-11-21 Preparacion de anticuerpos de cultivos de celula de ovario de hamster chino para conjugacion. MX2016006551A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361908568P 2013-11-25 2013-11-25
PCT/US2014/066889 WO2015077605A1 (en) 2013-11-25 2014-11-21 Preparing antibodies from cho cell cultures for conjugation

Publications (1)

Publication Number Publication Date
MX2016006551A true MX2016006551A (es) 2016-09-06

Family

ID=53180202

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006551A MX2016006551A (es) 2013-11-25 2014-11-21 Preparacion de anticuerpos de cultivos de celula de ovario de hamster chino para conjugacion.

Country Status (14)

Country Link
US (2) US10457976B2 (es)
EP (1) EP3074036B1 (es)
JP (2) JP6529188B2 (es)
KR (1) KR102306493B1 (es)
CN (1) CN105979963B (es)
AU (1) AU2014352824B2 (es)
CA (1) CA2928238C (es)
DK (1) DK3074036T3 (es)
EA (1) EA034123B1 (es)
ES (1) ES2753269T3 (es)
IL (1) IL245190B (es)
MX (1) MX2016006551A (es)
SG (2) SG10201710475WA (es)
WO (1) WO2015077605A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150083689A (ko) * 2014-01-10 2015-07-20 삼성전자주식회사 항 c-Met 항체 정제 방법
EP3252158A4 (en) 2015-01-26 2018-07-18 Kaneka Corporation Mutant immunoglobulin kappa chain variable region-binding peptide
WO2016121701A1 (ja) 2015-01-26 2016-08-04 株式会社カネカ 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス
EP3394082B1 (en) * 2015-12-21 2020-08-12 Pfizer Inc Purification of antibody drug conjugates using a sodium phosphate gradient
WO2017195638A1 (ja) * 2016-05-09 2017-11-16 株式会社カネカ 抗体またはκ鎖可変領域含有抗体断片の精製方法
WO2018116269A1 (en) * 2016-12-22 2018-06-28 Lupin Limited Depth filtration of a protein
SG11202111938YA (en) * 2019-05-03 2021-11-29 Genentech Inc Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
MX2022001626A (es) 2019-08-06 2022-03-02 Glaxosmithkline Ip Dev Ltd Composiciones biofarmaceuticas y procedimientos conexos.
KR20240040786A (ko) 2021-08-03 2024-03-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 생물제약 조성물 및 안정한 동위원소 표지 펩티드 맵핑 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JP2000503639A (ja) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー 分枝ヒドラゾンのリンカー類
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
AU2003263964C1 (en) 2002-07-31 2010-08-19 Seagen Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
ES2579836T3 (es) 2003-11-06 2016-08-17 Seattle Genetics, Inc. Compuestos de monometilvalina capaces de conjugación con ligandos
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
WO2007109163A2 (en) * 2006-03-16 2007-09-27 Amgen Inc Wash buffer and method of using
PE20091434A1 (es) * 2007-10-30 2009-10-17 Genentech Inc Purificacion de anticuerpos por cromatografia de intercambio cationico
KR101238061B1 (ko) 2009-03-31 2013-02-27 한화케미칼 주식회사 Ｖｃａｍ－１에 특이적으로 결합하는 인간 단일클론항체 및 그를 포함하는 염증성 질환 또는 암의 치료용 조성물
MX2012011900A (es) 2010-04-15 2013-03-21 Seattle Genetics Inc Conjugados de pirrolobenzodiazepina diana.
EP2822971B1 (en) * 2012-03-07 2018-07-18 Yeda Research and Development Co. Ltd. Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer

Also Published As

Publication number Publication date
EA201691094A1 (ru) 2016-09-30
KR102306493B1 (ko) 2021-09-28
KR20160089454A (ko) 2016-07-27
AU2014352824B2 (en) 2019-07-18
WO2015077605A1 (en) 2015-05-28
IL245190B (en) 2021-02-28
EP3074036A1 (en) 2016-10-05
CA2928238C (en) 2021-08-17
US20170159099A1 (en) 2017-06-08
CN105979963B (zh) 2020-03-03
JP2019048888A (ja) 2019-03-28
EA034123B1 (ru) 2019-12-30
ES2753269T3 (es) 2020-04-07
JP6529188B2 (ja) 2019-06-12
DK3074036T3 (da) 2019-11-18
SG10201710475WA (en) 2018-01-30
AU2014352824A1 (en) 2016-05-12
EP3074036A4 (en) 2017-07-26
US10457976B2 (en) 2019-10-29
EP3074036B1 (en) 2019-09-18
IL245190A0 (en) 2016-06-30
CA2928238A1 (en) 2015-05-28
US20200063180A1 (en) 2020-02-27
CN105979963A (zh) 2016-09-28
JP2016539130A (ja) 2016-12-15
SG11201602995VA (en) 2016-05-30

Similar Documents

Publication Publication Date Title
MX2016006551A (es) Preparacion de anticuerpos de cultivos de celula de ovario de hamster chino para conjugacion.
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
PH12016502586A1 (en) Lipid comprising docosapentaenoic acid
PH12015501017A1 (en) Alternative uses for hbv assembly effectors
PH12015501953A1 (en) Substituted nucleotide analogs
EA201300915A1 (ru) Новый европейский штамм prrsv
EA201492057A1 (ru) Ферментация и способ с псевдодвижущимся слоем
PH12015500040B1 (en) Supercritical hydrolysis of biomass
EA201690529A1 (ru) Способы модификации клетки-хозяина
MY163490A (en) Processing of organic matter
GB0917002D0 (en) Improved shigella blebs
IT1398553B1 (it) Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
EA201490886A1 (ru) Переработка биомассы
MX2017007196A (es) Fibroblastos de embrion de pollo inmortalizados.
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
EA201692473A1 (ru) Способы получения замещенных нуклеотидных аналогов
UY34582A (es) Anticuerpos anti-cxcr3
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
TW201612308A (en) Collector architecture layout design
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
EA201690718A1 (ru) Способ обработки целлюлозосодержащей биомассы
GB201017519D0 (en) Vaccines
EA201790250A1 (ru) Способ выделения полиовируса из культур клеток